Molecular and Systems Oncology Team

I am a first-year PhD student focusing on understanding angiosarcomas. My work involves molecular profiling of angiosarcoma patient samples to better understand mechanisms of treatment response and resistance and identify potential biomarkers.

I am currently working on utilising radiogenomics to understand heterogeneity and therapy response in soft tissue sarcoma, and whether combining imaging and molecular data can improve patient outcomes.

I am a first year PhD student and my work will be focussed on analysing post translational modifications, particularly phosphoproteomics by mass spectrometry in soft tissue sarcomas.

I am an administrative assistant within the Division of Molecular Pathology. I have a keen interest in the world of oncology and am enthusiastic about supporting those who are making a real difference in their work.

I began my postdoctoral career at the ICR in 2015. Initially working for the Signal Transduction Team (Barbara Tanos) and subsequently joining the Molecular and Systems Oncology Team in 2018. My current research is focused on understanding sub-clonal interactions and tumour heterogeneity driving EGFR inhibitor resistance in lung cancer.

I am a first-year PhD student split between Imperial College London (Ishihara lab) and the Institute of Cancer Research (Huang lab). My research will be focused on the bioengineering and development of immunomodulatory agents designed to target the extracellular matrix as a novel therapeutic strategy to treat sarcoma.

I am a PhD student and my research focuses on understanding kinase inhibitor resistance mechanisms in soft tissue sarcomas and lung cancers. To do this I am also working to develop better 2D and 3D sarcoma and lung models which are more similar to tumours in the body.

I am a Scientific Officer in the lab, working on tackling EGFR Exon 20 mutations in lung cancer.

I am interested in the proteomics of the extracellular matrix during breast cancer progression and in SWATH mass spectrometry development for clinical proteomics.

I am a 1st year PhD student and I’ll be using proteomics to better understand mechanisms of chemoresistance in soft tissue sarcoma (STS), characterising extracellular proteins and associated proteins (matrisome) to do this.

I am a PhD student working to understand the mechanisms of response and resistance in alveolar soft part sarcoma to the TKI cediranib, with the aims of identifying new biomarkers and therapeutic strategies to improve patient outcome.

I have recently, successfully completed a PhD in the Huang Lab at the ICR and now continue my work as a postdoctoral training fellow to identify novel strategies to overcome de novo resistance to EGFR inhibitors in lung cancer.